uniQure Financials - Benzinga

uniQure NV

QURENASDAQ

Trade with Public

Trade with Public

$46.23

-1.63-3.41%

At close: Sep 2, 5:00 PM EST

$46.23

N/A

After Hours: 4:00 PM EST

PRO

Why Is It Moving?™:uniQure shares are trading higher after the company announced the submissio...

Overview News Earnings Forecast Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

uniQure Financials

uniQure (QURE) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
uniQure Q2 EPS $(1.22) Misses $(0.82) Estimate, Sales $5.800M Beat $5.467M Estimate

uniQure (NASDAQ:QURE) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(0.82) by 48.78 percent. This is a 76.81 percent decrease over losses of $(0.69) per share from the

Benzinga Newsdesk

Earnings Scheduled For May 5, 2026

Benzinga Insights

PRO
uniQure Q1 EPS $(0.85), Inline, Sales $3.562M Miss $5.223M Estimate

uniQure (NASDAQ:QURE) reported quarterly losses of $(0.85) per share which met the analyst consensus estimate. This is a 3.66 percent decrease over losses of $(0.82) per share from the same period last year. The company

Benzinga Newsdesk

Stock Market Today: Dow, Nasdaq 100, S&P 500 Futures Plunge As Oil Prices Jump, Trump Dismisses 'Short Term' Spike— Hims & Hers In Focus (UPDATED)

Editor’s Note: The future prices of benchmark tracking ETFs and the headline were updated in the story.

Rishabh Mishra

These Analysts Cut Their Forecasts On uniQure Following Q4 Results

uniQure (NASDAQ:QURE) reported positive Q4 results, but FDA advised against using data for market application of AMT-130. Stock down 13.3%.

Avi Kapoor

uniQure Stock Plunges 40% After FDA Shocker

FDA urges uniQure to run a new trial for AMT-130, sending QURE shares down nearly 40% in premarket trading.

Vandana Singh